ALEX: Alectinib versus Crizotinib in ALK+ NSCLC - 100459

Spotlight
Video

ALEX: Alectinib versus Crizotinib in ALK+ NSCLC

moasc has 333 videos Subscribe Here

Loading........
Description: Viola Zhu, MD, PhD of UC Irvine Health discusses the ALEX trial and the use of alectinib and crizotinib in ALK+ non-small cell lung cancer at the 2017 MOASC Spotlight on Clinical Oncology in Huntington Beach, CA.

Abstract LBA9008: ALEX: Alectinib versus Crizotinib in ALK+ NSCLC at the First-Line Setting.
Shared By : moasc
Posted on : 08/02/17
Added : 1 year ago